#United States #Chicago #AI Platform #Coreline Soft #AVIEW 2.0

Coreline Soft Unveils AVIEW 2.0 at RSNA 2025

In an exciting development for the medical community, Coreline Soft has announced the unveiling of its cutting-edge chest AI platform, AVIEW 2.0, at RSNA 2025, scheduled to take place from November 30 to December 4 in Chicago. This innovative platform is designed to revolutionize the workflow standards in radiology, providing enhanced diagnostic capabilities for pulmonary, cardiac, and airway conditions.

AVIEW 2.0 signifies a major departure from traditional, task-specific diagnostic tools. Instead, it offers an integrated ecosystem that enables seamless combinations of various diagnostic tasks, specifically lung-cancer screening (LCS), coronary artery calcium scoring (CAC), and chronic obstructive pulmonary disease (COPD) quantification. By consolidating these processes into a unified analytical pipeline, this platform allows radiologists to streamline their workflows significantly, achieving up to an 89% increase in case throughput and a 60% reduction in interpretation times compared to its predecessor.

Global Impact and Validation

This robust clinical foundation for AVIEW extends far beyond pilot implementations. Having processed over 2.5 million cases across 19 countries, AVIEW 2.0 has established itself as a proven technology within diverse healthcare systems. Most significantly, it has been adopted as the standard AI platform for lung cancer screening initiatives in key European nations, including Germany, France, and Italy.

This shift indicates a broader acceptance of AI in healthcare, evolving from being perceived merely as a supportive diagnostic tool to becoming vital infrastructure within medical contexts. The rollout of guidelines in Germany and other EU member states that recommend the integration of AI into lung screening routines positions the market for exponential growth across the continent.

Adoption in the U.S.

Beyond Europe, Coreline's AVIEW solutions are making inroads into prominent medical facilities across the United States. For example, UMass Memorial Medical Center has implemented AVIEW as a comprehensive platform for lung cancer screening, coronary artery disease assessment, and COPD diagnosis—integrating it into the daily operations of thoracic radiology.

Furthermore, institutions like Temple Lung Center, 3DR Labs, and ImageCare Radiology have successfully incorporated AVIEW into their unique research and diagnostic frameworks, further showcasing the platform's adaptability to meet site-specific workflows and clinical needs.

Together, these case studies confirm that AVIEW 2.0 serves as more than just a test model; it represents a solution that fits seamlessly into real-world hospital operations while maintaining compliance with stringent clinical standards adopted by top-tier U.S. healthcare providers.

The Future of AI in Radiology

Coreline's COO, James Lee, expressed, "We see RSNA 2025 as proof that the intrinsic value of AI has transcended theoretical boundaries. When diagnostic efficiency and safety advancements occur concurrently, AI transcends its status as an add-on and transitions into essential healthcare infrastructure."

AVIEW 2.0 not only embodies this evolution but also promises to deliver sustainable foundations for large-scale precision medicine, where efficiency, accuracy, and wide-scale applicability converge as core principles.

Additionally, during RSNA 2025, Coreline Soft will host a live demonstration of the end-to-end AI workflow in the "Radiology Reimagined" demo zone. Attendees will witness the complete continuum—from initial triage and interpretation to comprehensive reporting and quality assurance—validated against respected standards like IHE and FHIR, providing a firsthand experience of AVIEW's integrated processes.

Event Information

• - Event: RSNA 2025
• - Location: McCormick Place, South Hall Level 3, Booth #4929
• - Dates: November 30 – December 4, 2025

To learn more about the event, visit Coreline Soft Events.

As the healthcare landscape continues to evolve, the introduction of AVIEW 2.0 marks a monumental moment in harnessing AI's capabilities for improving patient care and operational efficiency in radiology.